Get the latest market trends in your inbox
Stay on top of the latest market trends and economic insights with the Axios Markets newsletter. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Minneapolis-St. Paul
Tampa-St. Petersburg news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa-St. Petersburg
Johnson & Johnson and Bayer will pay $775 million to settle lawsuits over the blood thinner Xarelto, the New York Times reports.
The big picture: Patients said the drug caused massive, sometimes fatal bleeding, though the companies are not admitting any liability as part of the settlement. And a $775 million settlement is just a fraction of Xarelto's sales. Bayer brought in more than $4 billion in revenue from the drug last year, while J&J reported roughly $2.5 billion in Xarelto sales, according to Reuters. The companies developed the drug together and will split the settlement equally.
Go deeper: The drug pricing war that leaves patients caught in the middle